NASDAQ:NVNO enVVeno Medical (NVNO) Stock Price, News & Analysis → get a piece of the profit from this land (From True Market Insiders) (Ad) Free NVNO Stock Alerts $4.99 +0.04 (+0.81%) (As of 05/17/2024 ET) Add Compare Share Share Today's Range$4.95▼$5.1050-Day Range$4.62▼$6.4852-Week Range$2.51▼$6.97Volume51,190 shsAverage Volume47,838 shsMarket Capitalization$66.52 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get enVVeno Medical alerts: Email Address enVVeno Medical MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish6.81% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$51,837 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.40) to ($0.67) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.02 out of 5 starsMedical Sector903rd out of 920 stocksSurgical & Medical Instruments Industry99th out of 99 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for enVVeno Medical.Read more about enVVeno Medical's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.81% of the float of enVVeno Medical has been sold short.Short Interest Ratio / Days to CoverenVVeno Medical has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in enVVeno Medical has recently increased by 6.61%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldenVVeno Medical does not currently pay a dividend.Dividend GrowthenVVeno Medical does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NVNO. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for enVVeno Medical this week, compared to 0 articles on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, enVVeno Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $51,837.00 in company stock.Percentage Held by Insiders17.00% of the stock of enVVeno Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.71% of the stock of enVVeno Medical is held by institutions.Read more about enVVeno Medical's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for enVVeno Medical are expected to grow in the coming year, from ($1.40) to ($0.67) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of enVVeno Medical is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of enVVeno Medical is -3.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioenVVeno Medical has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about enVVeno Medical's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceBible Shocker: Have You Seen Elon Musk’s Miracle?Breaking News: Elon Musk Invents New Type of A.I. (Shocking) Elon Musk is about to shock the world again with this new type of A.I.… Minting new millionaires in the process.Click here for the full story… About enVVeno Medical Stock (NASDAQ:NVNO)enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI). Deep venous CVI occurs when valves inside of the deep veins of the leg become damaged, resulting in insufficient blood being returned to the heart. The malfunctioning vein valves cause blood to flow backwards (reflux) and pool in the lower leg, increasing the pressure within the veins of the leg (venous hypertension). In the most severe cases, CVI can lead to venous ulcers (open skin sores) that become chronic and difficult to heal. The VenoValve is implanted in the femoral vein and works as a replacement venous valve, designed to reduce reflux and venous hypertension, and to restore proper directional blood flow back to the heart. With severe deep venous CVI impacting an estimated 2.4 million people in the U.S., who have no effective treatment options, the VenoValve has received Breakthrough Device Designation from the U.S. Food and Drug Administration, and is currently being evaluated in the SAVVE U.S. clinical trial. Read More NVNO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NVNO Stock News HeadlinesMay 17 at 1:58 AM | americanbankingnews.comAnalyzing Vivos (OTCMKTS:RDGL) and enVVeno Medical (NASDAQ:NVNO)May 9, 2024 | msn.comNVNO Stock Earnings: enVVeno Medical Beats EPS for Q1 2024May 8, 2024 | finance.yahoo.comenVVeno Medical Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 24, 2024 | finance.yahoo.comenVVeno Medical Corporation (NVNO)April 24, 2024 | finance.yahoo.comPositive 11 Month Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical's VenoValve(R) Pivotal Trial to be Presented Today at the 46th Annual Charing Cross SymposiumApril 16, 2024 | finance.yahoo.comNew Topline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the 46th Annual Charing Cross Symposium on April 24, 2024April 11, 2024 | uk.investing.comenVVeno Medical hires new CCO to guide transitionApril 10, 2024 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Appoints Andrew Cormack as Its Chief Commercial OfficerApril 9, 2024 | finance.yahoo.comenVVeno Medical Appoints Andrew Cormack as Its Chief Commercial OfficerMarch 16, 2024 | finance.yahoo.comNVNO Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comenVVeno Medical to Participate in the Virtual Investor Lunch Break: The enVVeno OpportunityMarch 6, 2024 | finance.yahoo.comPositive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve(R) Pivotal Trial to be Presented Today at the VENOUS2024 American Venous Forum Annual MeetingMarch 3, 2024 | finance.yahoo.comCompanies Like enVVeno Medical (NASDAQ:NVNO) Are In A Position To Invest In GrowthFebruary 29, 2024 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateFebruary 29, 2024 | benzinga.comRecap: enVVeno Medical Q4 EarningsFebruary 29, 2024 | finance.yahoo.comenVVeno Medical Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate UpdateFebruary 20, 2024 | finance.yahoo.comTopline Efficacy Data from the enVVeno Medical VenoValve(R) Pivotal Trial to be Presented at the VENOUS2024 American Venous Forum Annual Meeting on March 6, 2024January 6, 2024 | finance.yahoo.comenVVeno Medical Corporation's (NASDAQ:NVNO) Path To ProfitabilityDecember 29, 2023 | ca.finance.yahoo.comNVNO Jan 2024 5.000 callDecember 14, 2023 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Posts Company Highlights and Materials from 2023 VEITH SymposiumDecember 14, 2023 | finance.yahoo.comenVVeno Medical Posts Company Highlights and Materials from 2023 VEITH SymposiumNovember 16, 2023 | finance.yahoo.comenVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the VenoValve Pivotal Trial at the 50th Annual VEITH SymposiumOctober 26, 2023 | finanznachrichten.deenVVeno Medical Corporation: enVVeno Medical Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateOctober 26, 2023 | msn.comenVVeno Medical files to sell 14.71M shares for holdersOctober 26, 2023 | msn.comenVVeno Medical reports Q3 resultsSee More Headlines Receive NVNO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for enVVeno Medical and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/19/2024Next Earnings (Estimated)7/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:NVNO CUSIPN/A CIK1661053 Webwww.hancockjaffe.com Phone(949) 261-2900Fax949-261-2992Employees19Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-23,520,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.17% Return on Assets-57.58% Debt Debt-to-Equity RatioN/A Current Ratio29.08 Quick Ratio29.08 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.18 per share Price / Book1.57Miscellaneous Outstanding Shares13,330,000Free Float11,064,000Market Cap$66.52 million OptionableOptionable Beta1.10 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesRobert Andrew BermanChief Executive Officer & DirectorCraig T. GlynnChief Financial Officer & TreasurerMarc H. GlickmanChief Medical Officer & Senior Vice PresidentHamed AlaviVice President-Research, Development & QualityKey CompetitorsPro-DexNASDAQ:PDEXMonogram OrthopaedicsNASDAQ:MGRMSEP AcquisitionNASDAQ:SEPANeuroneticsNASDAQ:STIMHealth Sciences Acquisitions Co. 2NASDAQ:HSAQView All CompetitorsInsiders & InstitutionsKingdon Capital Management L.L.C.Bought 34,690 shares on 5/16/2024Ownership: 4.905%Quadrature Capital LtdBought 18,872 shares on 5/15/2024Ownership: 0.142%Vanguard Group Inc.Bought 237,550 shares on 5/10/2024Ownership: 4.310%Acadian Asset Management LLCBought 6,825 shares on 5/10/2024Ownership: 0.051%RIA Advisory Group LLCBought 43,666 shares on 5/3/2024Ownership: 0.328%View All Insider TransactionsView All Institutional Transactions NVNO Stock Analysis - Frequently Asked Questions How have NVNO shares performed in 2024? enVVeno Medical's stock was trading at $5.14 at the beginning of 2024. Since then, NVNO shares have decreased by 2.9% and is now trading at $4.99. View the best growth stocks for 2024 here. When is enVVeno Medical's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, July 29th 2024. View our NVNO earnings forecast. How were enVVeno Medical's earnings last quarter? enVVeno Medical Corporation (NASDAQ:NVNO) issued its quarterly earnings results on Wednesday, May, 8th. The company reported ($0.31) earnings per share for the quarter. Who are enVVeno Medical's major shareholders? enVVeno Medical's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Kingdon Capital Management L.L.C. (4.91%), Vanguard Group Inc. (4.31%), RIA Advisory Group LLC (0.33%), Janney Montgomery Scott LLC (0.26%), Fermata Advisors LLC (0.17%) and Quadrature Capital Ltd (0.14%). Insiders that own company stock include Francis Duhay, Gmt Capital Corp, Hamed Alavi, Marc H Glickman, Matthew Jenusaitis, Robert Andrew Berman, Robert Gray and Sanjay Shrivastava. View institutional ownership trends. How do I buy shares of enVVeno Medical? Shares of NVNO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NVNO) was last updated on 5/19/2024 by MarketBeat.com Staff From Our PartnersBuy this small stock before coming AI Tidal WaveChaikin AnalyticsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingShocking $16T Elon Musk Crypto LeakCrypto 101 MediaForget Bitcoin: This $8 Stock Is the Next Big ThingBehind the MarketsDems have chosen Biden replacement?Paradigm PressHow Biden has already won 2024Porter & CompanyExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA letter is coming from the "Bureau of the Fiscal Service".Stansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding enVVeno Medical Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.